Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,400 full-time employees. The company went IPO on 2018-09-20. The firm is engaged in delivering products and services to prevent and treat disease in farm animals and pets. The company serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. The company includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. The company offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. The company offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Elanco Animal Health Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Elanco Animal Health Inc 주요 수익원은 Pet Health이며, 최신 수익 발표에서 수익은 2,300,000,000입니다. 지역별로는 United States이 Elanco Animal Health Inc의 주요 시장이며, 수익은 2,234,000,000입니다.
Elanco Animal Health Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Elanco Animal Health Inc의 순손실은 $0입니다.